Exufiber ® range Technology matters clinically

With Hydrolock® Technology

and Exufiber ® Ag+

Exufiber® dressings efficiently transfer exudate

• Absorbs and transfers exudate1–5

• Reduces the risk of exudate pooling in the wound bed2–4

Exufiber Ag+ prevents the reformation of biofilm7–13

• Starts to kill a wide range of pathogens within 3 hours (in vitro) 7–9

• Sustained antimicrobial effect up to 7 days (in vitro)7-9

• Prevents biofilm reformation (in vivo). Recommended as part of an holistic biofilm management approach including cleansing, debridement and clinical reassessement as per international guidelines10–13

Exufiber dressings support a clean wound bed upon dressing removal

• Superior* lock-in capacity5

• Stays intact and leaves no residues2–4, 6

• Promotes autolytic debridement3

Managing chronic exuding wounds is challenging and takes time. Innovation in technology can support clinicians in their wound management objectives. The Exufiber® range with Hydrolock® Technology is the next generation of gelling fibers that aim to improve patient outcomes and to create an optimal healing environment.

*when comparing lab test results for retention under pressure with Aquacel®, Aquacel® ExtraTM, Durafiber® and UrgoClean® dressings.

Simulation in a cavity wound model after adding 5 ml of Solution A showing exudate transfer of Exufiber and the leading gelling fiber brand after 5 min.

Baseline (Day 1): Wound bed covered in fibrin/sloughy tissue and with a non-vibrant granulation tissue indicating wound stasis, possibly due to an increased bacterial load.

In an in vivo model it was shown that Exufiber® Ag+ was superior over Aquacel® Ag+ Extra™ in reducing both MRSA and Pseudomonas Aeruginosa biofilm10–11.

Log

CFU

/g P

. aer

ugin

osa

0

10

9

8

7

6

5

4

3

2

1

Day 7Day 5Baseline Day 3

Aquacel® Ag+ Extra™

Exufiber® Ag+

Untreated control

Bacterial counts of biofilm after treatment

Pseudomonas aeruginosa

Exufiber® Leading gelling fiber brand

After 14 days of treatment with Exufiber® the wound bed looks clean and has a more vibrant and red/pink colour, indicating a healthy wound bed.

Viewed under a microscope, you can see that Exufiber® dressings are made of tightly packed fibres to minimise the free space for fluid or exudate to flow, keeping it locked in. This structure simultaneously increases the integrity of the entire dressing to stay intact, without the need for reinforcing threads to hold it together.

Moist wound management is fundamental for optimal wound healing14. Excess fluid may lead to maceration and delayed wound healing.

Exufiber® dressings efficiently transfer exudate from the wound bed to the secondary dressing1, while locking in exudate to minimise leakage and reducing the risk for maceration2–5, 15. It is important to avoid excess exudate being left in the wound, especially in deep cavity wounds.

Residues and debris can trigger a foreign body response and disturb healing16. Exufiber® dressings promote autolytic debridement3, lock in exudate and stay intact both during use and at removal2-6. The superior* lock in capacity5 provides a moist wound healing and supports a clean wound bed, aimed at reducing additional nursing time for cleaning.

Biofilms are present in almost all chronic, non-healing wounds and their presence prevent healing. By reducing the number of microorganisms, Exufiber Ag+ can prevent the re-formation of biofilm (in vivo)10,11. Exufiber® Ag+ is recommended as part of an holistic biofilm management approach including cleansing, debridement and clinical reassessement as per international guidelines13. Exufiber® Ag+ also provides antimicrobial effect up to seven days on a broad range of pathogens7–11.

‘Exudate can delay healing when in the wrong amount, in the wrong place, or of the wrong composition. Effective assessment and management of exudate is therefore key to ensuring timely wound healing without complications.’ – World Union of Wound Healing Societies (WUWHS) Consensus Document. Wound exudate: effective assessment and management, Wounds International, 2019.

Evolving gelling fibre dressings with Hydrolock® Technology

Transfer wound exudate

Supports clean wound bed

Prevent biofilm reformation

Find out more at www.molnlycke.comMölnlycke Health Care AB, P.O. Box 13080, Gamlestadsvägen 3 C, SE-402 52 Göteborg, Sweden. Phone + 46 31 722 30 00. The Mölnlycke, Exufiber and Hydrolock trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care group of companies. ©2020 Mölnlycke Health Care AB. All rights reserved. HQIM000654

Aquacel and Aquacel Extra are registered trademarks of ConvaTec Inc. Durafiber is a registered trademark of Smith & Nephew. UrgoClean is a registered trademark of Urgo Medical.

Aquacel® gelling fibre dressing

Exufiber® gelling fibre dressing

*when comparing lab test results for retention under pressure with Aquacel®, Aquacel® ExtraTM, Durafiber® and UrgoClean® dressings.

References: 1. Mölnlycke Health Care. Data on file. (2018). 2. Chadwick P, McCardle J. Open, non-comparative, multicenter post clinical study of the performance and safety of a gelling fibre wound dressing on diabetic foot ulcers. Journal of Wound Care 2016; 25(4): 290-300. 3. Smet, S., Beele, H., Saine, L., Suys, E., Henrickx, B. Open, non-comparative, multi-centre post market clinical follow-up investigation to evaluate performance and safety on pressure ulcers when using a gelling fibre dressing as intended. Poster Presentation at European Pressure Ulcer Advisory Panel Conference, 2015, Ghent, Belgium. 4. Davies, P., McCarty, S., An in-use product evaluation of a gelling fibre dressing in wound management. E-poster presentation at Wounds UK Conference, 2017, Harrogate, United Kingdom. 5. Surgical Materials Testing Laboratory. TM-404 Free Swell Absorption and Retention. Mölnlycke Health Care. Data on file. (2014). 6. Swerea IVF/Molnlycke Health Care. Test method T-1117 rev. 0. Mölnlycke Health Care. Data on file. (2014). 7. Mölnlycke Health Care. CE: Performance of Exufiber Ag+ in vitro; Antimicrobial effect, silver release kinetics and minimal effective concentration. (Data on file, 2016.). 8. Hamberg K., Gerner E. and Falkbring S., Mölnlycke Health Care, Gothenburg, Sweden. “Antimicrobial effect of a new silver-containing gelling fibre dressing against common wound pathogens”. Poster presented at the Symposium on Advanced Wound Care Spring meeting/Wound Healing Society (WHS) Annual Meeting 2017, Apr 05 - 09, 2017, San Diego, CA, USA. 9. Hamberg K.,Gerner E. and Falkbring S., Mölnlycke Health Care, Gothenburg, Sweden. “In vitro evaluation of the antimicrobial effect of silver-containing fibre dressings”. Poster presented at the Symposium on Advanced Wound Care Spring meeting/Wound Healing Society (WHS) Annual Meeting 2017, Apr 05 - 09, 2017, San Diego, CA, USA. 10. Gil et al. 2017. Evaluation of a Gelling Fiber Dressing with Silver to Eliminate MRSA Biofilm Infections and Enhance the Healing. Poster presented at the Symposium on Advanced Wound Care Spring meeting/Wound Healing Society (WHS) Annual Meeting 2017, Apr 05 - 09, 2017, San Diego, CA, USA. 11. Davis, S. C., Li, J. , Gil, J., Head, C. , Valdes, J., Glinos, G. D., Solis, M., Higa, A. and Pastar, I., Preclinical evaluation of a novel silver gelling fiber dressing on Pseudomonas aeruginosa in a porcine wound infection model. Wound Rep Reg 2019, 27: 360-365. 12. Gerner E., Hamberg K. and Falkbring S., Mölnlycke Health Care, Gothenburg, Sweden. ‘Activity of a new silver-containing gelling fibre dressing against biofilm (in vitro)’. Poster presented at the Symposium on Advanced Wound Care Spring meeting/Wound Healing Society (WHS) Annual Meeting 2017, Apr 05 - 09, 2017, San Diego, CA, USA. 13. (WUWHS), Florence Congress, Position Document. Management of Biofilm. London: Wounds International 2016 Bjarnsholt T, Eberlein T, Malone M, Schultz G. Management of wound biofilm Made Easy. London: Wounds International 2017. 14. World Union of Wound Healing Societies (WUWHS) Consensus Document. Wound exudate: effective assessment and management, Wounds International, 2019. 15. Mölnlycke Health Care. Data on file. (2014). 16. McGrath A (2011) Overcoming the challenge of overgranulation. Wounds UK 7(1): 42–9.